METHODOLOGICAL AND CONDUCT PRINCIPLES FOR PHARMACOECONOMIC RESEARCH

被引：54

作者：

CLEMENS, K ^{[1
]}

TOWNSEND, R ^{[1
]}

LUSCOMBE, F ^{[1
]}

MAUSKOPF, J ^{[1
]}

OSTERHAUS, J ^{[1
]}

BOBULA, J ^{[1
]}

机构：

[1] ROCHE PHARMACEUT,PALO ALTO,CA

来源：

PHARMACOECONOMICS | 1995年 / 8卷 / 02期

关键词：

D O I：

10.2165/00019053-199508020-00008

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

In January 1995, the Pharmaceutical Research and Manufacturers of America (PhRMA) adopted a voluntary set of principles to provide guidance for its member companies on the conduct and evaluation of pharmacoeconomic research. The principles were prepared by a working group of pharmacoeconomic scientists from the PhRMA Task Force on the Economic Evaluation of Pharmaceuticals. The principles were reviewed by a panel of academic experts and outside reviewers at each stage of their development. The PhRMA document consists of a set of broad principles that will foster high quality pharmacoeconomic research without impeding further methodological development of the field. Specific recommendations are offered in those methodological areas for which general agreement exists. However, no attempt was made to force a consensus for those methodological issues which have yet to be resolved. The principles address methodology and reporting of research rather than sponsor-investigator relationships or conflict of interest issues, which have been addressed elsewhere. This approach is based on the belief that the scientific integrity of pharmacoeconomic research is best ensured through the soundness of the research methods used and the full disclosure and transparency of all methods, analyses and results.

引用

页码：169 / 174

页数：6

共 24 条

[1] Guidelines for economic evaluation of pharmaceuticals, (1994)
[2] Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses, (1992)
[3] Drummond M., Brandt A., Luce B., Et al., Standardizing methodologies for economic evaluation in healthcare: practice, problems, and potential, Int J Technol Assess Health Care, 9, 1, pp. 26-36, (1993)
[4] Drummond M.F., Davies L., Economic analysis alongside clinical trials: revisiting the methodological issues, Int J Technol Assess Health Care, 7, 4, (1991)
[5] Drummond M.E., Economic evaluation of pharmaceuticals: science or marketing?, PharmacoEconornics, 1, 1, pp. 8-13, (1992)
[6] Freund D.A., Dittus R.S., Principles of pharmacoeconomic analysis of drug therapy, PharmacoEconomics, 1, 1, (1992)
[7] Luce B.R., Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals, PharmacoEconomics, 3, 1, pp. 1-9, (1993)
[8] Bootman J.L., Larson L.N., McGhan W.F., Et al., Pharmacoeconomic research and clinical trials: concepts and issues, DICP Ann Pharmacother, 23, (1989)
[9] Maynard A., The design of future cost-benefit studies, Am Heart J, 199, (1990)
[10] Johannesson M., Johansson P-O, Jonsson B., Economic evaluation of drug therapy: a review of the contingent valuation method, PharmacoEconomics, 1, 5, (1992)

← 1 2 3 →